ClinicalTrials.gg

Program

pimicotinib

Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.

Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Mar 13, 202314 company-led studies, 6 open or runningNext primary completion: Aug 22, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman135 open or runningphase 3since Mar 13, 2023Nov 27, 2019Dec 31, 2031phase 1 · NCT04192344
Merck KGaA, Darmstadt, Germany11 open or runningphase 2since Mar 23, 2026Mar 23, 2026Aug 22, 2028phase 2 · NCT07499362

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 27, 2019.

  1. Mar 7, 2022Phase 1 study in NeoplasmsAbbisko Cayman · NCT05280483 · 16 enrolled · China
  2. Mar 13, 2023Phase 3 study in Giant Cell Tumor of Tendon SheathAbbisko Cayman · NCT05804045 · 94 enrolled · United States, Canada, China and more
  3. Oct 20, 2023Phase 2 study in Advanced Pancreatic CancerAbbisko Cayman · NCT06111274 · 82 planned · China
  4. Nov 20, 2023Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06186583 · 6 enrolled · China
  5. Nov 28, 2023Phase 2 study in cGvHDAbbisko Cayman · NCT06186804 · 64 planned · China
  6. Feb 29, 2024Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06322706 · 36 enrolled · China
  7. Aug 18, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06562946 · 24 enrolled · China
  8. Nov 14, 2024Phase 1 study in PharmacokineticsAbbisko Cayman · NCT06694948 · 26 enrolled · China
  9. Jan 9, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06779253 · 39 enrolled · China
  10. Mar 13, 2025Phase 1 study in Healthy SubjectsAbbisko Cayman · NCT06884072 · 16 enrolled · China
  11. Aug 3, 2025Phase 1 study in PharmacokineticsAbbisko Cayman · NCT07126249 · 38 enrolled · China
  12. Sep 30, 2025Phase 1 study in Pharmacokinetics in Healthy VolunteersAbbisko Cayman · NCT07210996 · 20 enrolled · China
  13. Mar 23, 2026Merck KGaA, Darmstadt, Germany's first study: phase 2 study in Giant Cell Tumor of Tendon SheathNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT07499362 · 20 planned · Japan
  14. Nov 9, 2026Primary completion moved from 2026-12-31 to 2031-12-31Date moved laterphase 1 · +60 months · NCT04192344

Ahead

  1. Aug 22, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathMerck KGaA, Darmstadt, Germany · NCT07499362
  2. Dec 31, 2031Primary completion: phase 1 study in NeoplasmsAbbisko Cayman · NCT04192344

TargetBeta

CSF1R →read by rule
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
axatilimabruleIncytephase 312
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07499362Giant Cell Tumor of Tendon Sheath · Japan2RecruitingMerck KGaA, Darmstadt, GermanyAug 22, 202820
NCT07210996Pharmacokinetics in Healthy Volunteers · China1CompletedAbbisko CaymanOct 6, 202520
NCT07126249Pharmacokinetics · China1CompletedAbbisko CaymanJun 6, 202538
NCT06884072Healthy Subjects · China1Active, not recruitingAbbisko CaymanJul 1, 202516
NCT06779253Healthy Subjects · China1CompletedAbbisko CaymanApr 4, 202539
NCT06694948Pharmacokinetics · China1CompletedAbbisko CaymanJan 3, 202526
NCT06562946Pharmacokinetics · China1CompletedAbbisko CaymanDec 30, 202424
NCT06322706Healthy Subjects · China1CompletedAbbisko CaymanNov 1, 202436
NCT06186804cGvHD · China2By invitationAbbisko CaymanOct 30, 202664
NCT06186583Healthy Subjects · China1CompletedAbbisko CaymanMay 30, 20246
NCT06111274Advanced Pancreatic Cancer · China2RecruitingAbbisko CaymanDec 30, 202582
NCT05804045Giant Cell Tumor of Tendon Sheath · United States, Canada, China and more3Active, not recruitingAbbisko CaymanSep 23, 202494
NCT05280483Neoplasms · China1CompletedAbbisko CaymanAug 31, 202216
NCT04192344Neoplasms · United States, China1RecruitingAbbisko CaymanDec 31, 2031276

How it is read

Names in the registry

  • “pimicotinib capsules”, 4 entries
  • “ABSK021”, 3 entries
  • “Pimicotinib”, 2 entries
  • “Pimicotinib(ABSK021)”, 1 entry
  • “Pimicotinib capsule”, 1 entry

Codes read as this program: ABSK021.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.